Literature DB >> 29429629

Matrix metalloproteinase 12 promotes tumor propagation in the lung.

Ezra Ella1, Yaniv Harel1, Michal Abraham1, Hanna Wald1, Ofra Benny2, Adi Karsch-Bluman2, Dive Vincent3, Devel Laurent3, Gail Amir4, Uzi Izhar5, Oz M Shapira5, David Yoon6, Hyun-Sung Lee6, David J Sugarbaker6, Bryan Burt6, Amnon Peled1, Ori Wald7.   

Abstract

OBJECTIVE: Past studies are inconsistent with regard to the role of matrix metalloproteinase 12 in lung tumorigenesis. This is due, in part, to differential tumorigenesis based on tumor-derived versus immune-derived matrix metalloproteinase 12 expression. Our study aims to thoroughly dissect the role of matrix metalloproteinase 12 in lung tumorigenesis.
METHODS: We tested matrix metalloproteinase 12 expression and the association with prognosis using a tissue array and a published non-small cell lung cancer gene expression database. In addition, we characterized the contribution of matrix metalloproteinase 12 to tumor propagation in the lung using a series of in vitro and in vivo studies.
RESULTS: Tumor cells of a diverse set of human lung cancers stained positive for matrix metalloproteinase 12, and high matrix metalloproteinase 12 mRNA levels in the tumor were associated with reduced survival. The lung microenvironment stimulated endogenous production of matrix metalloproteinase 12 in lung cancer cells (human 460 lung cancer cell line, Lewis lung carcinoma). In vitro, matrix metalloproteinase 12 knockout Lewis lung carcinoma and Lewis lung carcinoma cells had the same proliferation rate, but Lewis lung carcinoma showed increased invasiveness. In vivo, deficiency of matrix metalloproteinase 12 in Lewis lung carcinoma cells, but not in the host, reduced tumor growth and invasiveness.
CONCLUSIONS: We suggest that tumor cell-derived matrix metalloproteinase 12 promotes tumor propagation in the lung and that in the context of pulmonary malignancies matrix metalloproteinase 12 should further be tested as a potential novel therapeutic target.
Copyright © 2018 The American Association for Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  lung; non–small cell lung cancer; orthotopic animal model; tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 29429629     DOI: 10.1016/j.jtcvs.2017.11.110

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  Novel Matrix Metalloproteinase 12 Selective Radiotracers for Vascular Molecular Imaging.

Authors:  Jakub Toczek; Thomas Bordenave; Kiran Gona; Hye-Yeong Kim; Fabrice Beau; Dimitris Georgiadis; Isabelle Correia; Yunpeng Ye; Mahmoud Razavian; Jae-Joon Jung; Olivier Lequin; Vincent Dive; Mehran M Sadeghi; Laurent Devel
Journal:  J Med Chem       Date:  2019-10-25       Impact factor: 7.446

2.  Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential.

Authors:  Jeppe Thorlacius-Ussing; Stephanie Nina Kehlet; Sarah Rank Rønnow; Morten Asser Karsdal; Nicholas Willumsen
Journal:  J Cancer Res Clin Oncol       Date:  2018-11-22       Impact factor: 4.553

3.  Cobalt-induced oxidative stress contributes to alveolar/bronchiolar carcinogenesis in B6C3F1/N mice.

Authors:  Thai-Vu T Ton; Ramesh C Kovi; Teja N Peddada; Raveena M Chhabria; Keith R Shockley; Norris D Flagler; Kevin E Gerrish; Ronald A Herbert; Mamta Behl; Mark J Hoenerhoff; Robert C Sills; Arun R Pandiri
Journal:  Arch Toxicol       Date:  2021-09-01       Impact factor: 6.168

4.  Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis.

Authors:  Jianguo Zhang; Jianzhong Zhang; Cheng Yuan; Yuan Luo; Yangyi Li; Panpan Dai; Wenjie Sun; Nannan Zhang; Jiangbo Ren; Junhong Zhang; Yan Gong; Conghua Xie
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

5.  DRP1 contributes to head and neck cancer progression and induces glycolysis through modulated FOXM1/MMP12 axis.

Authors:  Tai-Lin Huang; Chuang-Rung Chang; Chih-Yen Chien; Gong-Kai Huang; Yi-Fan Chen; Li-Jen Su; Hsin-Ting Tsai; Yu-Sheng Lin; Fu-Min Fang; Chang-Han Chen
Journal:  Mol Oncol       Date:  2022-04-15       Impact factor: 7.449

6.  Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model.

Authors:  Laurent Devel; Gunter Almer; Claudia Cabella; Fabrice Beau; Mylène Bernes; Paolo Oliva; Fabrice Navarro; Ruth Prassl; Harald Mangge; Isabelle Texier
Journal:  Molecules       Date:  2019-09-26       Impact factor: 4.411

7.  MMP12 is a potential therapeutic target for Adamantinomatous craniopharyngioma: Conclusions from bioinformatics analysis and in vitro experiments.

Authors:  Minde Li; Lin Zhou; Shaoyang Li; Linchun Fang; Le Yang; Xiao Wu; Chenxing Yang; Youyuan Bao; Sihai Lan; Zhigao Tong; Suyue Zheng; Bin Tang; Erming Zeng; Shenhao Xie; Cheng Chen; Tao Hong
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 2.967

8.  Mmp12 Is Upregulated by in utero Second-Hand Smoke Exposures and Is a Key Factor Contributing to Aggravated Lung Responses in Adult Emphysema, Asthma, and Lung Cancer Mouse Models.

Authors:  Alexandra Noël; Zakia Perveen; Rui Xiao; Harriet Hammond; Viviana Le Donne; Kelsey Legendre; Manas Ranjan Gartia; Sushant Sahu; Daniel B Paulsen; Arthur L Penn
Journal:  Front Physiol       Date:  2021-11-29       Impact factor: 4.566

9.  Matrix metalloproteinase 12 is an independent prognostic factor predicting postoperative relapse of conventional renal cell carcinoma - a short report.

Authors:  Bence Beres; Maria Yusenko; Lehel Peterfi; Gyula Kovacs; Daniel Banyai
Journal:  Cell Oncol (Dordr)       Date:  2021-12-11       Impact factor: 6.730

10.  Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.

Authors:  Pancheng Wu; Yi Zheng; Yanyu Wang; Yadong Wang; Naixin Liang
Journal:  J Transl Med       Date:  2020-10-07       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.